Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Arm Phase 2 Study of Daratumumab Subcutaneous (SC) in Previously Treated STK11/LKB1 Mutated Non-small Cell Lung Cancer

NCT05807048 is registered in ClinicalTrials.gov with NYU Langone Health as lead sponsor.

NCT NCT05807048
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05807048 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Arm Phase 2 Study of Daratumumab Subcutaneous (SC) in Previously Treated STK11/LKB1 Mutated Non-small Cell Lung Cancer
Lead sponsor
NYU Langone Health
Phase
Phase 2
Overall status
Completed
Start date
June 1, 2023
Completion date
November 11, 2025
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer with stk11/lkb1 mutation